Please use this identifier to cite or link to this item:
https://doi.org/10.1007/s00280-006-0270-1
| Title: | Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG) | Authors: | Yeo, W. Zee, B. Ma, B. Lam, K.C. Mo, F.K.F. Ng, E.K.W. Ho, R. Chan, A.T.C. Yeo, W. Boyer, M. Clarke, S. Beale, P. Chung, H.C. Roh, J.K. Rha, S.Y. Jeung, H.C. Ong, S.Y.K. Lim, R. Soo, R. Goh, B.C. |
Keywords: | First line chemotherapy Irofulven Stomach cancer |
Issue Date: | 2007 | Citation: | Yeo, W., Zee, B., Ma, B., Lam, K.C., Mo, F.K.F., Ng, E.K.W., Ho, R., Chan, A.T.C., Yeo, W., Boyer, M., Clarke, S., Beale, P., Chung, H.C., Roh, J.K., Rha, S.Y., Jeung, H.C., Ong, S.Y.K., Lim, R., Soo, R., Goh, B.C. (2007). Irofulven as first line therapy in recurrent or metastatic gastric cancer: A phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). Cancer Chemotherapy and Pharmacology 59 (3) : 295-300. ScholarBank@NUS Repository. https://doi.org/10.1007/s00280-006-0270-1 | Source Title: | Cancer Chemotherapy and Pharmacology | URI: | http://scholarbank.nus.edu.sg/handle/10635/27257 | ISSN: | 03445704 | DOI: | 10.1007/s00280-006-0270-1 |
| Appears in Collections: | Staff Publications |
Show full item record
Files in This Item:
There are no files associated with this item.
SCOPUSTM
Citations
15
checked on Jan 26, 2022
WEB OF SCIENCETM
Citations
14
checked on Jan 18, 2022
Page view(s)
220
checked on Jan 20, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.